General Information of Drug (ID: DMI5XR1)

Drug Name
LPA Drug Info
Synonyms
2-Hydroxy-3-(phosphonooxy)propyl oleate; lysophosphatidic acid; 1-Oleoyl-lyso-phosphatidic acid; Monooleylphosphatidic acid; Oleoyl lysophosphatidic acid; 1-Oleyllysophosphatidic acid; 22002-87-5; (2-hydroxy-3-phosphonooxypropyl) (Z)-octadec-9-enoate; 1-oleoyl-LPA; monooleylphosphatidate; [3H]1-oleoyl-LPA; [3H]lysophosphatidic acid; [3H]LPA; 1-oleoyl-lysophosphatidic acid; [3H]-LPA; AC1NUZKL; Lysophosphophatidic acid; Oleoyl lysophosphatidate; 1-Oleyllysophosphatidate; 1-Oleoyl-lysophosphatidate; lysophosphatidic acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5497152
ChEBI ID
CHEMBL1222042
CAS Number
CAS 22002-87-5
TTD Drug ID
DMI5XR1

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Investigative Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
dioctanoylglycerol pyrophosphate DM0QY1V Discovery agent N.A. Investigative [2]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Siponimod DM2R86O Multiple sclerosis 8A40 Approved [14]
Fingolimod DM5JVAN Multiple sclerosis 8A40 Approved [15]
Ozanimod DMT6AM2 Multiple sclerosis 8A40 Approved [16]
Etrasimod DMT0A3Y Ulcerative colitis DD71 Approved [17]
Ponesimod DMEAOYJ Multiple sclerosis 8A40 Approved [18]
MT-1303 DMSE9TH Crohn disease DD70 Phase 2 [19]
ONO-4641 DMLUM3Y Rheumatoid arthritis FA20 Phase 2 [20]
KRP-203 DMOW9X2 Cutaneous lupus erythematosus EB5Z Phase 2 [20]
VTX-002 DMZ8Z5A Ulcerative colitis DD71 Phase 2 [21]
CBP-307 DM3TH6Y Ulcerative colitis DD71 Phase 2 [22]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
N-arachidonoylglycine DM85RJ1 Discovery agent N.A. Investigative [23]
alkyl glycerol phosphate 18:1 DM3DERI Discovery agent N.A. Investigative [24]
octyl thiophosphatidic acid DM2RJYO Discovery agent N.A. Investigative [24]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ki16425 DMJTDK9 Discovery agent N.A. Investigative [25]
dioctanoylglycerol pyrophosphate DM0QY1V Discovery agent N.A. Investigative [25]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ki16425 DMJTDK9 Discovery agent N.A. Investigative [26]
2-oleoyl-LPA DMN9OS1 Discovery agent N.A. Investigative [27]
dodecyl-thiophosphate DMAJVPI Discovery agent N.A. Investigative [28]
oleoyl-thiophosphate DM1TAM9 Discovery agent N.A. Investigative [28]
NAEPA DM38XWZ Discovery agent N.A. Investigative [29]
BrP-LPA DMPGEO1 Discovery agent N.A. Investigative [30]
dodecylphosphate DMPCLTW Discovery agent N.A. Investigative [31]
PMID18178086C15 DMA2OWK Discovery agent N.A. Investigative [32]
decyl dihydrogen phosphate DMNKDT5 Discovery agent N.A. Investigative [31]
GRI977143 DM3A0TE Discovery agent N.A. Investigative [33]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
[1-bromo-(3S)-hydrox-4-(palmitoyloxy)butyl]phosphate DMS1YN3 Discovery agent N.A. Investigative [29]
Drug Name Drug ID Indication ICD 11 Highest Status REF
SAR-100842 DMDMQW0 Fibrosis GA14-GC01 Phase 2 [34]
BMS-986020 DMHMV6E Scleroderma 4A42 Phase 2 [17]
BMS-986278 DMD27RW Pulmonary fibrosis CB03.4 Phase 2 [35]
BMS-986337 DM9GC6L Pulmonary fibrosis CB03.4 Phase 1 [36]
BMS-986202 DM8TAI9 Idiopathic pulmonary fibrosis CB03.4 Preclinical [37]
Ki16425 DMJTDK9 Discovery agent N.A. Investigative [38]
dioctanoylglycerol pyrophosphate DM0QY1V Discovery agent N.A. Investigative [39]
2-oleoyl-LPA DMN9OS1 Discovery agent N.A. Investigative [27]
dodecyl-thiophosphate DMAJVPI Discovery agent N.A. Investigative [28]
oleoyl-thiophosphate DM1TAM9 Discovery agent N.A. Investigative [40]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SAR-100842 DMDMQW0 Fibrosis GA14-GC01 Phase 2 [34]
Ki16425 DMJTDK9 Discovery agent N.A. Investigative [26]
dioctanoylglycerol pyrophosphate DM0QY1V Discovery agent N.A. Investigative [39]
2-oleoyl-LPA DMN9OS1 Discovery agent N.A. Investigative [27]
dodecyl-thiophosphate DMAJVPI Discovery agent N.A. Investigative [28]
oleoyl-thiophosphate DM1TAM9 Discovery agent N.A. Investigative [28]
VPC12249 DM6F0VR Discovery agent N.A. Investigative [41]
NAEPA DM38XWZ Discovery agent N.A. Investigative [29]
dodecylphosphate DMPCLTW Discovery agent N.A. Investigative [31]
VPC32183 DMLK3I9 Discovery agent N.A. Investigative [42]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [43]
Quercetin DM3NC4M Obesity 5B81 Approved [44]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [45]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [46]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [47]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [48]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [49]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [50]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [51]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [52]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [44]
Testosterone DM7HUNW Hot flushes GA30 Approved [53]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [53]
Leflunomide DMR8ONJ Arthritis FA20 Approved [54]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [44]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [55]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [56]
Arsenic DMTL2Y1 N. A. N. A. Approved [57]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [58]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [59]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [60]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [61]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [62]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [63]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [64]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [65]
Secobarbital DM14RF5 Epilepsy 8A60-8A68 Approved [66]
Gefitinib DM15F0X Colon adenocarcinoma Approved [67]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [68]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [69]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ethanol DMDRQZU Chronic pain MG30 Approved [70]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [61]
Carvedilol DMHTEAO Chronic heart failure BD1Z Approved [71]
Paclitaxel DMLB81S Breast carcinoma Approved [72]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [73]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [60]
Urokinase DM0GOUD Myocardial infarction BA41-BA43 Approved [74]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [75]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [63]
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [64]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Laminin subunit beta-3 (LAMB3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [76]
Selenium DM25CGV N. A. N. A. Approved [77]
Methotrexate DM2TEOL Anterior urethra cancer Approved [78]
Methylprednisolone DM4BDON Acute adrenal insufficiency Approved [78]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [79]
Testosterone DM7HUNW Hot flushes GA30 Approved [53]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [80]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [81]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [55]
Palbociclib DMD7L94 Breast cancer 2C60-2C65 Approved [82]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [83]
Mechlorethamine DM0CVXA Chronic myelogenous leukaemia 2A20.0 Approved [84]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [76]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [85]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [86]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [85]
Panobinostat DM58WKG Chronic graft versus host disease Approved [87]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [88]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [89]
Palbociclib DMD7L94 Breast cancer 2C60-2C65 Approved [82]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [90]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [90]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [91]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [92]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [93]
Clodronate DM9Y6X7 Hypercalcaemia 5B91.0 Approved [92]
Cidofovir DMA13GD Cytomegalovirus infection 1D82 Approved [92]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [94]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [55]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [92]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [95]
Quercetin DM3NC4M Obesity 5B81 Approved [44]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [96]
Panobinostat DM58WKG Chronic graft versus host disease Approved [87]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [47]
Testosterone DM7HUNW Hot flushes GA30 Approved [53]
Acocantherin DM7JT24 Atrial fibrillation BC81.3 Approved [97]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [53]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [94]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [55]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
G protein coupled receptor 87 (GPR87) TTO897C GPR87_HUMAN Agonist [2]
Lysophosphatidate-3 receptor (LPAR3) TTE2YJR LPAR3_HUMAN Agonist [3]
Lysophosphatidic acid receptor 1 (LPAR1) TTQ6S1K LPAR1_HUMAN Agonist [4]
Lysophosphatidic acid receptor 2 (LPAR2) TTB7Y8I LPAR2_HUMAN Agonist [5]
Lysophosphatidic acid receptor 4 (LPAR4) TT7ZMY4 LPAR4_HUMAN Agonist [6]
Lysophosphatidic acid receptor 5 (LPAR5) TTABCJ6 LPAR5_HUMAN Agonist [7]
Lysophosphatidic acid receptor 6 (LPAR6) TTZDAGB LPAR6_HUMAN Agonist [8]
P2Y purinoceptor 10 (P2RY10) TTMFOU6 P2Y10_HUMAN Agonist [2]
Sphingosine-1-phosphate receptor 1 (S1PR1) TT9JZCK S1PR1_HUMAN Agonist [9]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Laminin subunit alpha-3 (LAMA3) OTFME7HT LAMA3_HUMAN Gene/Protein Processing [10]
Laminin subunit beta-3 (LAMB3) OTFPU6W8 LAMB3_HUMAN Gene/Protein Processing [10]
Laminin subunit gamma-2 (LAMC2) OTJMTM72 LAMC2_HUMAN Gene/Protein Processing [10]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Post-Translational Modifications [11]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Post-Translational Modifications [11]
Myosin light chain kinase, smooth muscle (MYLK) OT78QB4A MYLK_HUMAN Drug Response [12]
Myosin regulatory light polypeptide 9 (MYL9) OT6B22JB MYL9_HUMAN Post-Translational Modifications [13]
Rho-related GTP-binding protein RhoC (RHOC) OTOLE1FT RHOC_HUMAN Gene/Protein Processing [13]
Vascular endothelial growth factor A, long form OTIM9MZ3 VEGFA_HUMAN Gene/Protein Processing [11]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5395).
2 Identification of the orphan GPCR, P2Y(10) receptor as the sphingosine-1-phosphate and lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2008 Jul 11;371(4):707-12.
3 Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J Biol Chem. 1999 Sep 24;274(39):27776-85.
4 Diversity of lysophosphatidic acid receptor-mediated intracellular calcium signaling in early cortical neurogenesis. J Neurosci. 2010 May 26;30(21):7300-9.
5 Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3473-6.
6 Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem. 2003 Jul 11;278(28):25600-6.
7 Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen. 2013 Jun;18(5):599-609.
8 G protein-coupled receptor P2Y5 and its ligand LPA are involved in maintenance of human hair growth. Nat Genet. 2008 Mar;40(3):329-34.
9 Lysophosphatidic acid stimulates the G-protein-coupled receptor EDG-1 as a low affinity agonist. J Biol Chem. 1998 Aug 21;273(34):22105-12.
10 Increase of laminin 5 synthesis in human keratinocytes by acute wound fluid, inflammatory cytokines and growth factors, and lysophospholipids. Br J Dermatol. 2004 Nov;151(5):961-70. doi: 10.1111/j.1365-2133.2004.06175.x.
11 Hypoxia enhances LPA-induced HIF-1alpha and VEGF expression: their inhibition by resveratrol. Cancer Lett. 2007 Dec 8;258(1):63-9. doi: 10.1016/j.canlet.2007.08.011. Epub 2007 Oct 4.
12 Regulation of LPA-promoted myofibroblast contraction: role of Rho, myosin light chain kinase, and myosin light chain phosphatase. Exp Cell Res. 2000 Feb 1;254(2):210-20. doi: 10.1006/excr.1999.4754.
13 Use of synthetic isoprenoids to target protein prenylation and Rho GTPases in breast cancer invasion. PLoS One. 2014 Feb 26;9(2):e89892. doi: 10.1371/journal.pone.0089892. eCollection 2014.
14 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
15 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
16 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
17 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
18 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
19 Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs. 2015 Jul;29(7):565-75.
20 Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond. Nat Rev Drug Discov. 2013 Sep;12(9):688-702.
21 Clinical pipeline report, company report or official report of Ventyx Biosciences
22 Clinical pipeline report, company report or official report of Connect Biopharma
23 Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92. J Biol Chem. 2008 Jul 25;283(30):21054-64.
24 Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. J Biol Chem. 2009 Jun 19;284(25):17304-19.
25 The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. Biochem Biophys Res Commun. 2007 Nov 23;363(3):861-6.
26 Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol. 2003 Oct;64(4):994-1005.
27 Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors. FEBS Lett. 2000 Jul 28;478(1-2):159-65.
28 Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activ... J Med Chem. 2005 Jul 28;48(15):4919-30.
29 LPA and its analogs-attractive tools for elucidation of LPA biology and drug development. Curr Med Chem. 2008;15(21):2122-31.
30 Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res. 2009 Jul 1;69(13):5441-9.
31 Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2003 May;63(5):1032-42.
32 Discovery of potent LPA2 (EDG4) antagonists as potential anticancer agents. Bioorg Med Chem Lett. 2008 Feb 1;18(3):1037-41.
33 Virtual screening for LPA2-specific agonists identifies a nonlipid compound with antiapoptotic actions. Mol Pharmacol. 2012 Dec;82(6):1162-73.
34 Promising Pharmacological Directions in the World of Lysophosphatidic Acid Signaling. Biomol Ther (Seoul) 2015 January; 23(1): 1-11.
35 Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respir Res. 2021 Dec;8(1):e001026.
36 ClinicalTrials.gov (NCT04550195) A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study of the Safety and Tolerability, and Pharmacokinetics (Including Food Effect, pH Effect and Japanese Bridging Study) of BMS-986337 Following Oral Administration in Healthy Participants. U.S.National Institutes of Health.
37 Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. J Pharmacol Exp Ther. 2011 Mar;336(3):693-700.
38 Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. Int J Oncol. 2012 Apr;40(4):1133-41.
39 Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol. 2001 Oct;60(4):776-84.
40 Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors. Acta Pharmacol Sin. 2010 Sep;31(9):1213-22.
41 Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist. Mol Pharmacol. 2001 Dec;60(6):1173-80.
42 Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2735-40.
43 Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol. 2004 May;30(5):662-70. doi: 10.1165/rcmb.2003-0267OC. Epub 2003 Nov 20.
44 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
45 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
46 N-acylation of glucosamine modulates chondrocyte growth, proteoglycan synthesis, and gene expression. J Rheumatol. 2005 Sep;32(9):1775-86.
47 Grouping of histone deacetylase inhibitors and other toxicants disturbing neural crest migration by transcriptional profiling. Neurotoxicology. 2015 Sep;50:56-70.
48 Single-cell Transcriptome Mapping Identifies Common and Cell-type Specific Genes Affected by Acute Delta9-tetrahydrocannabinol in Humans. Sci Rep. 2020 Feb 26;10(1):3450. doi: 10.1038/s41598-020-59827-1.
49 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
50 Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer. 2008 May 1;122(9):2115-24. doi: 10.1002/ijc.23315.
51 Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
52 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
53 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
54 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
55 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
56 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
57 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
58 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
59 Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone. Steroids. 2008 Jan;73(1):116-28.
60 Treatment with anticancer agents induces dysregulation of specific Wnt signaling pathways in human ovarian luteinized granulosa cells in vitro. Toxicol Sci. 2013 Nov;136(1):183-92. doi: 10.1093/toxsci/kft175. Epub 2013 Aug 16.
61 Progesterone increases csk homologous kinase in HMC-1560 human mast cells and reduces cell proliferation. J Cell Biochem. 2007 Dec 1;102(5):1271-80. doi: 10.1002/jcb.21357.
62 Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK. Chem Biol Interact. 2017 Aug 1;273:107-114. doi: 10.1016/j.cbi.2017.06.005. Epub 2017 Jun 7.
63 Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway. Toxicol Sci. 2014 Feb;137(2):404-15. doi: 10.1093/toxsci/kft254. Epub 2013 Nov 5.
64 Growth stimulation of human pulmonary adenocarcinoma cells and small airway epithelial cells by beta-carotene via activation of cAMP, PKA, CREB and ERK1/2. Int J Cancer. 2006 Mar 15;118(6):1370-80. doi: 10.1002/ijc.21537.
65 Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis. Toxicol Appl Pharmacol. 2014 Mar 1;275(2):176-81. doi: 10.1016/j.taap.2014.01.005. Epub 2014 Jan 17.
66 Inhibition of activator protein 1 by barbiturates is mediated by differential effects on mitogen-activated protein kinases and the small G proteins ras and rac-1. J Pharmacol Exp Ther. 2004 Dec;311(3):1232-40. doi: 10.1124/jpet.104.071332. Epub 2004 Jul 19.
67 Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat. 2010 Feb;119(3):575-91. doi: 10.1007/s10549-009-0355-8. Epub 2009 Mar 15.
68 Effect of histamine H1 receptor antagonists on TARC/CCL17 and MDC/CCL22 production from CD14+ cells induced by antigenic stimulation in vitro. Int Arch Allergy Immunol. 2011;155(1):38-51. doi: 10.1159/000318720. Epub 2010 Nov 25.
69 SIRT3 Mediates the Antioxidant Effect of Hydrogen Sulfide in Endothelial Cells. Antioxid Redox Signal. 2016 Feb 20;24(6):329-43. doi: 10.1089/ars.2015.6331. Epub 2015 Nov 10.
70 Downregulation of mitogen-activated protein kinases (MAPKs) in chronic ethanol-induced fatty liver. Toxicol Mech Methods. 2020 Jul;30(6):407-416. doi: 10.1080/15376516.2020.1747126. Epub 2020 Apr 1.
71 A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007 Oct 16;104(42):16657-62. doi: 10.1073/pnas.0707936104. Epub 2007 Oct 9.
72 The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol. 2009 Nov;175(5):2226-34.
73 Modulation of apoptosis in HaCaT keratinocytes via differential regulation of ERK signaling pathway by flavonoids. J Biol Chem. 2005 Sep 9;280(36):31498-507. doi: 10.1074/jbc.M505537200. Epub 2005 Jul 13.
74 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
75 Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
76 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
77 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
78 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
79 A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
80 Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
81 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
82 Cdk4/6 inhibition induces epithelial-mesenchymal transition and enhances invasiveness in pancreatic cancer cells. Mol Cancer Ther. 2012 Oct;11(10):2138-48. doi: 10.1158/1535-7163.MCT-12-0562. Epub 2012 Aug 6.
83 Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
84 Histopathologic and immunohistochemical features in human skin after exposure to nitrogen and sulfur mustard. Am J Dermatopathol. 1998 Feb;20(1):22-8. doi: 10.1097/00000372-199802000-00005.
85 Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
86 Constitutive gene expression predisposes morphogen-mediated cell fate responses of NT2/D1 and 27X-1 human embryonal carcinoma cells. Stem Cells. 2007 Mar;25(3):771-8. doi: 10.1634/stemcells.2006-0271. Epub 2006 Nov 30.
87 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
88 Cyclosporine A--induced oxidative stress in human renal mesangial cells: a role for ERK 1/2 MAPK signaling. Toxicol Sci. 2012 Mar;126(1):101-13.
89 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
90 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
91 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
92 Transcriptomics hit the target: monitoring of ligand-activated and stress response pathways for chemical testing. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):7-18.
93 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
94 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
95 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
96 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
97 Ouabain impairs cell migration, and invasion and alters gene expression of human osteosarcoma U-2 OS cells. Environ Toxicol. 2017 Nov;32(11):2400-2413. doi: 10.1002/tox.22453. Epub 2017 Aug 10.